#AUA14 - Poster: Overactive bladder patients ≥ 65 years of age have a similar efficacy and safety profile with onabotulinumtoxinA as patients less than 65 years of age

ORLANDO, FL USA (UroToday.com) - Presented by Courtenay Moore,1 Albert Kaufmann,2 Manher Joshi,3 Christopher Nardo,3 Yan Zheng,4 and Sender Herschorn5 at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

aua 2014 moore age poster thumb

1Cleveland Clinic, Cleveland, OH, USA; 2Kliniken Maria Hilf GmbH, Mönchengladbach, Germany; 3Allergan, Inc., Irvine, CA, USA; 4Allergan, Inc., Bridgewater, NJ, USA; 5University of Toronto, Toronto, ON, Canada

 

 

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe